About ADYNOVATE

People with hemophilia A either don't have enough of, or have improperly working clotting factor VIII. It is believed that ADYNOVATE temporarily replaces the missing factor VIII to help control bleeds.1,2

ADYNOVATE is built on the ADVATE® [Antihemophilic Factor (Recombinant)] molecule, a prescription treatment that was FDA-approved to treat hemophilia A in 2003. However, ADYNOVATE is attached to a molecule called polyethylene glycol, or PEG, which allows it to last longer in the body than ADVATE.†1-3

Proprietary PEGylation Technology exclusively licensed from Nektar Therapeutics.

SELECTED IMPORTANT RISK INFORMATION

What important information do I need to know about ADYNOVATE and ADVATE?

  • You can have an allergic reaction to ADYNOVATE or ADVATE. Call your healthcare provider right away and stop treatment if you get a rash or hives, itching, tightness of the throat, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea or fainting.
  • Do not attempt to infuse yourself with ADYNOVATE or ADVATE unless you have been taught by your HCP or hemophilia center.

See Detailed Important Risk Information below.

Extended Half-Life with ADYNOVATE

Light bulb Icon.What does half-life mean?

Half-life describes how long it takes for the body to eliminate half of the dose of a product.4 For example, if the half-life of a product is 8 hours, then 8 hours after dosing, 50% of the dose remains in your bloodstream.

Light bulb Icon.What is PK?

Pharmacokinetics (or "PK") is the science of how a drug is used up in the body.3 A PK Profile for an individual person helps determine how quickly or slowly a person's body breaks down their treatment.8

Study designs

PK assessment for children under 12 years old
In a phase 3 clinical trial before starting prophylactic treatment with ADYNOVATE, a PK comparison of ADYNOVATE vs ADVATE in 31 children under 12 years old determined there was a 30% to 50% extension in half-life, depending on the lab test used.1,2

PK assessment for adolescents and adults 12 years and older
Before beginning prophylactic treatment with ADYNOVATE, a pharmacokinetic comparison of ADYNOVATE vs ADVATE in 26 patients (adolescents and adults 12 years and older) determined that ADYNOVATE has a 40% to 50% extension in half-life, depending on the lab test used.1,5

PEGylation—specifically chosen for ADYNOVATE

The scientists that developed ADYNOVATE deliberately chose PEGylation Technology because:6
  • It allows for a longer half-life while maintaining the integrity of the ADVATE protein2,6
  • It is a well-established technology

Proprietary PEGylation Technology exclusively licensed from Nektar Therapeutics.

Study results

ADYNOVATE was designed to stay in your body longer:

Water drop.In children under 12 years old

Statistical range of 30% to 50%.

in patients under 12 years old
ADYNOVATE lasted 30-50%
longer
than ADVATE2

Water drop.In adolescents and adults 12 years and older

Statistical range of 40% to 50%.

in patients 12 and older
ADYNOVATE lasted 40-50%
longer
than ADVATE5

Collage of man throughout different stages of his life.

Could ADYNOVATE mean 1 less infusion per week for you?

70% of adolescents and adults 12 years and older (69 out of 98) in a clinical study were able to reduce the frequency of prophylaxis dosing from their pre-study prophylaxis dosing regimen by 30% or more, which is approximately 1 fewer infusion per week. Talk to your doctor to learn what this could mean for you.5,7

Talk to your doctor to see if
ADYNOVATE is right for you.

Icon of pointing down arrow.Download discussion guide

Record your current bleed rate and work with your doctor to determine your goals.

Icon of pointing down arrow.Download my goals worksheet

SELECTED IMPORTANT RISK INFORMATION

What else should I know about ADYNOVATE and Hemophilia A?

Your body may form inhibitors to factor VIII. An inhibitor is part of the body's normal defense system. If you form inhibitors, it may stop ADYNOVATE from working properly. Talk with your HCP to make sure you are carefully monitored with blood tests for the development of inhibitors to factor VIII.

See Detailed Important Risk Information below.

Learn more about how ADYNOVATE works to control bleeds

How ADYNOVATE works in your body (11:18)

Putting patients first

Learn how TAKEDA continues to provide
product support for ADYNOVATE patients.

Learn More
Stories from people like you

Learn what real people with hemophilia A are saying about treatment with ADYNOVATE

See stories